Danilo Guerini

NIBR ATI, Switzerland

Danilo Guerini from 1978 to 1982 worked on his undergraduate studies in the school of Natural Sciences of the Swiss Federal Institute of Technology (ETH), Zürich, Switzerland. In 1982, he received a Diploma in Natural Sciences (biochemistry III), from 1982 to 1986, he worked on graduate studies at the Institute of Biochemistry III at ETHZ (with supervisors Professor E. Carafoli and Dr. J. Krebs), in 1986 he obtained the promotion as a Ph.D. degree in natural sciences on the interaction of Calmodulin with its target enzymes. From 1986 to 1991, he received a postdoctoral fellowship in the Laboratory of Biochemistry, Cancer Institute, National Institutes of Health (NIH), Bethesda, Md, USA. He also served at the Laboratory of Dr. C. Klee on cloning of both subunits of the Ca2+-dependent phosphatase calcineurin from different sources. From 1991 to 1999, he worked as an Oberassistent at the Laboratory of Biochemistry III, Federal Institute of Technology (ETH), Zürich, Switzerland. In 1998, he obtained the Venia Legendi at the ETH Zürich, a habilitation entitled “The Ca2+-calmodulin-regulated phosphatase calcineurin and the plasma membrane Ca2+ ATPase (PMCA).” From 1999 to 2002, he served as the Lab Head of Novartis Pharma AG, MCD, Obesity-Biology, focus on central regulatory peptide and GPCR signaling to control appetite: Orexin, BRS3, MCH1. Since 2002, he has been serving as a Senior Research Scientist; Novartis Institute for Biomedical Research (NIBR), Novartis Pharma, Basel, of the autoimmunity transplantation and inflammation (ATI). He work with several projects on calcium release-activated calcium channel protein 1 (CRAC), G-protein coupled receptor 183 (EBI2), lysophosphatidic acid receptor 1 (LPA1), signal peptide peptidase-like 2A (SPPL2a), FTY720 followup, Sphingosine 1-phosphate receptor 1 (agonist, antagonists), 4 (agonists), and 5 (agonists), and exploratory activities. He has support to development of FTY720 and the active component of Gylenia (novel multiple sclerosis drug). His fields of expertise include Ca2+ signaling in eucaryotic cells, with focus on lymphocytes (T and B cells); Plasma membrane; calcineurin. He works on molecular immunology of T and B cells, GPCR-dependent signaling, S1P1 biology, and exploratory drug development.

Biography Updated on 20 March 2012

Scholarly Contributions [Data Provided by scopus]